Segantii Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Segantii Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50,000	Closed	-$505K	–	446
2022 Q4	$505K	Hold	50,000	–	–	0.02%	274
2022 Q3	$496K	Hold	50,000	–	–	0.01%	361
2022 Q2	$495	Hold	50,000	–	–	0.01%	345
2022 Q1	$493K	Hold	50,000	–	–	0.01%	367
2021 Q4	$492K	Buy	+50,000	New	+$491K	0.02%	361

Segantii Capital Management's BIOT Position: Q1 2023 in Review

Segantii Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 50,000 shares — an estimated $505K sold.

Segantii Capital Management first reported a position in BIOT in Q4 2021 and held it in 5 quarters. The position peaked at $505K in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Segantii Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Segantii Capital Management sold 50,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $505K.
Segantii Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q4 2021 and held it in 5 quarters.
Segantii Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $505K in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Segantii Capital Management's 13F filing for Q1 2023, filed 5 May 2023.